CONFERENCE UPDATE: EHA 2021
Ravulizumab for adult patients with PNH and HDA: Two-year results from phase 3, open-label study
24 Sep 2021
CONFERENCE UPDATE: EHA 2021
Ravulizumab for adult patients with PNH and HDA: Two-year results from phase 3, open-label study